EVOLVE 104

Alternative Names: EV-104 - EvolveImmune Therapeutics; EVOLVE-104

Latest Information Update: 21 Apr 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EvolveImmune Therapeutics
Class Antibodies; Antineoplastics; Immunotherapies; Recombinant proteins
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

18 Apr 2023 Adverse events, pharmacokinetics and pharmacodynamics data from a preclinical trial in Lung cancer released by EvolveImmune Therapeutics
24 Oct 2022 EvolveImmune Therapeutics plans a first-in-human clinical trial in Solid tumours in 2024
13 Jul 2022 Preclinical trials in Solid tumours in USA (Parenteral) prior to July 2022 (EvolveImmune Therapeutics pipeline, July 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com